APOE immunotherapy
US8741298B2 · kind B2 · utility
1Cited by
0References
65Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 7, 2012 |
| Grant date | Jun 3, 2014 |
| Priority date | — |
| Expiry date | Feb 7, 2032 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/2821
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides antibodies that preferentially bind to an ApoE(1-272) fragment relative to ApoE(1-299). These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of neurological diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.